Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice

Grace Ifeyinwa Onimoe, Aiguo Liu, Li Lin, Chang Ching Wei, Eric B. Schwartz, Deepak Bhasin, Chenglong Li, James R. Fuchs, Pui Kai Li, Peter J Houghton, Amanda Termuhlen, Thomas Gross, Jiayuh Lin

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Constitutive activation of Signal Transducers and Activators of Transcription 3 (STAT3) is frequently detected in osteosarcoma, and hence, may serve as a therapeutic target. In order to target STAT3, we tested two new STAT3 inhibitors, LLL12 and FLLL32. LLL12 and FLLL32 inhibit STAT3 phosphorylation and STAT3 downstream targets. LLL12 and FLLL32 also inhibit IL-6 induced STAT3 phosphorylation. The inhibition of STAT3 by LLL12 and FLLL32 resulted in the induction of apoptosis, reduction of plating efficiency, and migration in osteosarcoma cells. Furthermore, LLL12 and FLLL32 inhibited SJSA osteosarcoma cells and OS-33 tumor growth in murine xenografts. These results provide evidence that constitutive STAT3 signaling is required for osteosarcoma survival and migration in vitro and tumor growth in vivo. Blocking persistent STAT3 signaling by LLL12 and FLLL32 may be a novel therapeutic approach for osteosarcoma.

Original languageEnglish (US)
Pages (from-to)916-926
Number of pages11
JournalInvestigational New Drugs
Volume30
Issue number3
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

STAT3 Transcription Factor
Osteosarcoma
Growth
Phosphorylation
FLLL 32
Heterografts
Interleukin-6
Neoplasms
Apoptosis

Keywords

  • Osteosarcoma
  • Small molecule inhibitors
  • STAT3

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. / Onimoe, Grace Ifeyinwa; Liu, Aiguo; Lin, Li; Wei, Chang Ching; Schwartz, Eric B.; Bhasin, Deepak; Li, Chenglong; Fuchs, James R.; Li, Pui Kai; Houghton, Peter J; Termuhlen, Amanda; Gross, Thomas; Lin, Jiayuh.

In: Investigational New Drugs, Vol. 30, No. 3, 01.06.2012, p. 916-926.

Research output: Contribution to journalArticle

Onimoe, GI, Liu, A, Lin, L, Wei, CC, Schwartz, EB, Bhasin, D, Li, C, Fuchs, JR, Li, PK, Houghton, PJ, Termuhlen, A, Gross, T & Lin, J 2012, 'Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice', Investigational New Drugs, vol. 30, no. 3, pp. 916-926. https://doi.org/10.1007/s10637-011-9645-1
Onimoe, Grace Ifeyinwa ; Liu, Aiguo ; Lin, Li ; Wei, Chang Ching ; Schwartz, Eric B. ; Bhasin, Deepak ; Li, Chenglong ; Fuchs, James R. ; Li, Pui Kai ; Houghton, Peter J ; Termuhlen, Amanda ; Gross, Thomas ; Lin, Jiayuh. / Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. In: Investigational New Drugs. 2012 ; Vol. 30, No. 3. pp. 916-926.
@article{6aeed58b17f840a7b552a271549d3228,
title = "Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice",
abstract = "Constitutive activation of Signal Transducers and Activators of Transcription 3 (STAT3) is frequently detected in osteosarcoma, and hence, may serve as a therapeutic target. In order to target STAT3, we tested two new STAT3 inhibitors, LLL12 and FLLL32. LLL12 and FLLL32 inhibit STAT3 phosphorylation and STAT3 downstream targets. LLL12 and FLLL32 also inhibit IL-6 induced STAT3 phosphorylation. The inhibition of STAT3 by LLL12 and FLLL32 resulted in the induction of apoptosis, reduction of plating efficiency, and migration in osteosarcoma cells. Furthermore, LLL12 and FLLL32 inhibited SJSA osteosarcoma cells and OS-33 tumor growth in murine xenografts. These results provide evidence that constitutive STAT3 signaling is required for osteosarcoma survival and migration in vitro and tumor growth in vivo. Blocking persistent STAT3 signaling by LLL12 and FLLL32 may be a novel therapeutic approach for osteosarcoma.",
keywords = "Osteosarcoma, Small molecule inhibitors, STAT3",
author = "Onimoe, {Grace Ifeyinwa} and Aiguo Liu and Li Lin and Wei, {Chang Ching} and Schwartz, {Eric B.} and Deepak Bhasin and Chenglong Li and Fuchs, {James R.} and Li, {Pui Kai} and Houghton, {Peter J} and Amanda Termuhlen and Thomas Gross and Jiayuh Lin",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s10637-011-9645-1",
language = "English (US)",
volume = "30",
pages = "916--926",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice

AU - Onimoe, Grace Ifeyinwa

AU - Liu, Aiguo

AU - Lin, Li

AU - Wei, Chang Ching

AU - Schwartz, Eric B.

AU - Bhasin, Deepak

AU - Li, Chenglong

AU - Fuchs, James R.

AU - Li, Pui Kai

AU - Houghton, Peter J

AU - Termuhlen, Amanda

AU - Gross, Thomas

AU - Lin, Jiayuh

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Constitutive activation of Signal Transducers and Activators of Transcription 3 (STAT3) is frequently detected in osteosarcoma, and hence, may serve as a therapeutic target. In order to target STAT3, we tested two new STAT3 inhibitors, LLL12 and FLLL32. LLL12 and FLLL32 inhibit STAT3 phosphorylation and STAT3 downstream targets. LLL12 and FLLL32 also inhibit IL-6 induced STAT3 phosphorylation. The inhibition of STAT3 by LLL12 and FLLL32 resulted in the induction of apoptosis, reduction of plating efficiency, and migration in osteosarcoma cells. Furthermore, LLL12 and FLLL32 inhibited SJSA osteosarcoma cells and OS-33 tumor growth in murine xenografts. These results provide evidence that constitutive STAT3 signaling is required for osteosarcoma survival and migration in vitro and tumor growth in vivo. Blocking persistent STAT3 signaling by LLL12 and FLLL32 may be a novel therapeutic approach for osteosarcoma.

AB - Constitutive activation of Signal Transducers and Activators of Transcription 3 (STAT3) is frequently detected in osteosarcoma, and hence, may serve as a therapeutic target. In order to target STAT3, we tested two new STAT3 inhibitors, LLL12 and FLLL32. LLL12 and FLLL32 inhibit STAT3 phosphorylation and STAT3 downstream targets. LLL12 and FLLL32 also inhibit IL-6 induced STAT3 phosphorylation. The inhibition of STAT3 by LLL12 and FLLL32 resulted in the induction of apoptosis, reduction of plating efficiency, and migration in osteosarcoma cells. Furthermore, LLL12 and FLLL32 inhibited SJSA osteosarcoma cells and OS-33 tumor growth in murine xenografts. These results provide evidence that constitutive STAT3 signaling is required for osteosarcoma survival and migration in vitro and tumor growth in vivo. Blocking persistent STAT3 signaling by LLL12 and FLLL32 may be a novel therapeutic approach for osteosarcoma.

KW - Osteosarcoma

KW - Small molecule inhibitors

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84864350035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864350035&partnerID=8YFLogxK

U2 - 10.1007/s10637-011-9645-1

DO - 10.1007/s10637-011-9645-1

M3 - Article

C2 - 21340507

AN - SCOPUS:84864350035

VL - 30

SP - 916

EP - 926

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -